logo
Plus   Neg
Share
Email

Lexicon Phase 2 Trial Of Anti-Tumor Drug Meets Primary Endpoint, Begins Phase 3

Lexicon Pharmaceuticals, Inc. (LXRX), a biopharmaceutical company announced new data from its recently completed Phase 2 study of its investigational drug telotristat etiprate for carcinoid tumors. Through the trial, the drug achieved its primary endpoint that is the reduction of bowel movements from baseline at week 12 in 46.4 percent of the patients involved in the study and suffering from metastatic carcinoid syndrome. In addition, the company said it would present the data from the trial at the North American Neuroendocrine Tumor Society on October 13 in California.

Further, the company added Telotristat etiprate, administered orally was well tolerated by the patients with only three of the patients reporting serious adverse events, none of which was related to study drug.

In a statement, the company said it is also initiating a 12-week registrational Phase 3 trail that is designed to test the drug's safety, efficacy after its positive outlook in the Phase 2 trials, said Lexicon in a statement.

For comments and feedback contact: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
After failing to sustain an initial upward move, stocks showed a lack of direction over the course of the trading session on Tuesday. The major averages pulled back off their early highs and spent the rest of the day bouncing back and forth across the unchanged line. Under pressure from President Donald Trump, Senate Majority Leader Mitch McConnell, R-Ken., announced Tuesday the Senate will hold a vote on a criminal justice reform bill before the end of the year. In a tense public exchange with Democratic leaders on Tuesday, President Donald Trump took ownership of a potential shutdown of key government agencies over the issue of funding of his controversial border wall. "If we don't get what we want, one way or the other," Trump said, "I will shut down the government, absolutely."
Follow RTT